[1]
|
Gordan, J.D., Kennedy, E.B., Abou-Alfa, G.K., et al. (2020) Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 38, 4317-4345. https://doi.org/10.1200/JCO.20.02672
|
[2]
|
Yang, J.D., Hainaut, P., Gores, G.J., et al. (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nature Reviews Gastroenterology & Hepatology, 16, 589-604.
https://doi.org/10.1038/s41575-019-0186-y
|
[3]
|
Hepatocellular Carcinoma. Nature Reviews Disease Primers, 7, Article No. 7.
https://doi.org/10.1038/s41572-021-00245-6
|
[4]
|
Yin, J., Bo, W.T., Sun, J., et al. (2017) New Evidence and Per-spectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Journal of Clinical and Translational Hepatology, 5, 169-176.
|
[5]
|
Yang, Z., Zou, R., Zheng, Y., et al. (2019) Lipiodol Deposition in Portal Vein Tumour Thrombus Predicts Treatment Outcome in HCC Patients after Transarterial Chemoembolisation. European Radiology, 29, 5752-5762.
https://doi.org/10.1007/s00330-019-06157-0
|
[6]
|
Kuo, Y.-H., Wu, I.P, Wang, J.-H., et al. (2017) The Outcome of Sorafenib Monotherapy on Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Investigational New Drugs, 36, 307-314.
https://doi.org/10.1007/s10637-017-0468-6
|
[7]
|
Su, G.L., Altayar, O., O’Shea, R., et al. (2022) AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Gastroenterology, 162, 920-934. https://doi.org/10.1053/j.gastro.2021.12.276
|
[8]
|
Bruix, J., Chan, S.L., Galle, P.R., Rimassa, L. and Sangro, B. (2021) Systemic Treatment of Hepatocellular Carcinoma: An EASL Position Paper. Journal of Hepatology, 75, 960-974. https://doi.org/10.1016/j.jhep.2021.07.004
|
[9]
|
Kudo, M., Kawamura, Y., Hasegawa, K., et al. (2021) Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 10, 181-223.
https://doi.org/10.1159/000514174
|
[10]
|
Cerrito, L., Annicchiarico, B.E., Iezzi, R., et al. (2019) Treatment of Hepa-tocellular Carcinoma in Patients with Portal Vein Tumor Thrombosis: Beyond the Known Frontiers. World Journal of Gastroenterology, 25, 4360-4382.
https://doi.org/10.3748/wjg.v25.i31.4360
|
[11]
|
中国医师协会肝癌专业委员会. 中国肝细胞癌合并门静脉癌栓诊疗指南(2021年版) [J]. 中华医学杂志, 2022, 102(4): 243-254.
|
[12]
|
Wu, B., Zhang, Y., Tan, H. and Shi, H. (2019) Value of 18F-FDG PET/CT in the Diagnosis of Portal Vein Tumor Thrombus in Patients with Hepatocellular Carcinoma. Abdominal Radiology, 44, 2430-2435.
https://doi.org/10.1007/s00261-019-01997-2
|
[13]
|
Kudo, M., Izumi, N., Kubo, S., et al. (2020) Report of the 20th Nationwide Follow-Up Survey of Primary Liver Cancer in Japan. Hepatology Research, 50, 15-46. https://doi.org/10.1111/hepr.13438
|
[14]
|
Shi, J., Lai, E.C., Li, N., et al. (2011) A New Classification for Hepatocel-lular Carcinoma with Portal Vein Tumor Thrombus. Journal of Hepato-Biliary-Pancreatic Sciences, 18, 74-80. https://doi.org/10.1007/s00534-010-0314-0
|
[15]
|
West, H.J. and Jin, J.O. (2015) Transarterial Chemoembolization. JAMA Oncology, 1, 1178.
https://doi.org/10.1001/jamaoncol.2015.3702
|
[16]
|
Niu, Z.J., Ma, Y.L., Kang, P., et al. (2012) Transarterial Che-moembolization Compared with Conservative Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Using a New Classification. Medical Oncology, 29, 2992-2997. https://doi.org/10.1007/s12032-011-0145-0
|
[17]
|
Xiang, X., Lau, W.Y., Wu, Z.Y., et al. (2019) Transarterial Che-moembolization versus Best Supportive Care for Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombusa Multicenter Study. European Journal of Surgical Oncology, 45, 1460-1467. https://doi.org/10.1016/j.ejso.2019.03.042
|
[18]
|
Ni, J.Y., Sun, H.L., Luo, J.H., et al. (2019) Transarterial Che-moembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy. Cancer Management and Research, 11, 9939-9950. https://doi.org/10.2147/CMAR.S224532
|
[19]
|
Langendijk, J.A., Boersma, L.J., Rasch, C.R.N., et al. (2018) Clini-cal Trial Strategies to Compare Protons with Photons. Seminars in Radiation Oncology, 28, 79-87. https://doi.org/10.1016/j.semradonc.2017.11.008
|
[20]
|
Huo, Y.R. and Eslick, G.D. (2015) Transcatheter Arterial Chemoembolization plus Radiotherapy Compared with Chemoembolization Alone for Hepatocellular Carcinoma: A Sys-tematic Review and Meta-analysis. JAMA Oncology, 1, 756-765. https://doi.org/10.1001/jamaoncol.2015.2189
|
[21]
|
Hu, H.T., Luo, J.P., Cao, G.S., et al. (2021) Hepatocellular Car-cinoma with Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs. 125Iodine Implantation. Frontiers in Oncology, 11, Article 806907. https://doi.org/10.3389/fonc.2021.806907
|
[22]
|
Sangro, B. and Salem, R. (2014) Transarterial Chemoembolization and Radioembolization. Seminars in Liver Disease, 34, 435-443. https://doi.org/10.1055/s-0034-1394142
|
[23]
|
Mikell, J.K., Dewaraja, Y.K. and Owen, D. (2020) Transarterial Ra-dioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Semi-nars in Radiation Oncology, 30, 68-76.
https://doi.org/10.1016/j.semradonc.2019.08.005
|
[24]
|
Kooby, D.A., Egnatashvili, V., Srinivasan, S., et al. (2010) Comparison of Yttrium-90 Radioembolization and Transcatheter Arterial Chemoembolization for the Treatment of Unre-sectable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 21, 224-230. https://doi.org/10.1016/j.jvir.2009.10.013
|
[25]
|
Salem, R., Gabr, A., Riaz, A., et al. (2018) Institutional Decision to Adopt Y90 as Primary Treatment for Hepatocellular Carcinoma Informed by a 1,000-Patient 15-Year Experience. Hepa-tology, 68, 1429-1440.
https://doi.org/10.1002/hep.29691
|
[26]
|
Mazzaferro, V., Sposito, C., Bhoori, S., et al. (2013) Yttrium-90 Radioem-bolization for Intermediate-Advanced Hepatocellular Carcinoma: A Phase 2 Study. Hepatology, 57, 1826-1837. https://doi.org/10.1002/hep.26014
|
[27]
|
Ahn, J.C., Lauzon, M., Luu, M., et al. (2021) Transarterial Radioemboliza-tion versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the US National Cancer Database. Journal of Nuclear Medicine, 62, 1692-1701. https://doi.org/10.2967/jnumed.121.261954
|
[28]
|
Lu, Z.H., Shen, F., Yan, Z.L., et al. (2009) Treatment of Portal Vein Tumor Thrombus of Hepatocellular Carcinoma with Percutaneous Laser Ablation. Journal of Cancer Research and Clinical Oncology, 135, 783-789.
https://doi.org/10.1007/s00432-008-0513-0
|
[29]
|
Tarantino, L., Busto, G., Nasto, A., et al. (2017) Percutaneous Electrochemotherapy in the Treatment of Portal Vein Tumor Thrombosis at Hepatic Hilum in Patients with Hepatocellular Carcinoma in Cirrhosis: A Feasibility Study. World Journal of Gastroenterology, 23, 906-918. https://doi.org/10.3748/wjg.v23.i5.906
|
[30]
|
Hong, T.S., Wo, J.Y., Yeap, B.Y., et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepato-cellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology, 34, 460-468. https://doi.org/10.1200/JCO.2015.64.2710
|
[31]
|
Tse, R.V., Hawkins, M., Lockwood, G., et al. (2008) Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarci-noma. Journal of Clinical Oncology, 26, 657-664.
https://doi.org/10.1200/JCO.2007.14.3529
|
[32]
|
Zhang, S., He, L., Bo, C., et al. (2021) Comparison of Stereotactic Body Radiation Therapy versus Fractionated Radiation Therapy for Primary Liver Cancer with Portal Vein Tumor Thrombus. Radiation Oncology, 16, Article No. 149.
https://doi.org/10.1186/s13014-021-01874-7
|
[33]
|
Kondo, M., Morimoto, M., Kobayashi, S., et al. (2019) Ran-domized, Phase II Trial of Sequential Hepatic Arterial Infusion Chemotherapy and Sorafenib versus Sorafenib Alone as Initial Therapy for Advanced Hepatocellular Carcinoma: SCOOP-2 Trial. BMC Cancer, 19, Article No. 954. https://doi.org/10.1186/s12885-019-6198-8
|
[34]
|
Kudo, M., Ueshima, K., Yokosuka, O., et al. (2018) Sorafenib plus Low-Dose Cisplatin and Fluorouracil Hepatic Arterial Infusion Chemotherapy versus Sorafenib Alone in Patients with Advanced Hepatocellular Carcinoma (SILIUS): A Randomised, Open Label, Phase 3 Trial. The Lancet Gastroen-terology & Hepatology, 3, 424-432.
https://doi.org/10.1016/S2468-1253(18)30078-5
|
[35]
|
He, M., Li, Q., Zou, R., et al. (2019) Sorafenib plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncology, 5, 953-960. https://doi.org/10.1001/jamaoncol.2019.0250
|
[36]
|
Choi, J.H., Chung, W.J., Bae, S.H., et al. (2018) Randomized, Prospective, Comparative Study on the Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancer Chemotherapy and Pharmacology, 82, 469-478.
https://doi.org/10.1007/s00280-018-3638-0
|
[37]
|
Lyu, N., Wang, X., et al. (2022) Arterial Chemotherapy of Oxali-platin plus Fluorouracil versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Random-ized, Phase III Trial (FOHAIC-1). Journal of Clinical Oncology, 40, 468-480. https://doi.org/10.1200/JCO.21.01963
|
[38]
|
Kokudo, T., Hasegawa, K., Matsuyama, Y., et al. (2016) Survival Benefit of Liver Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion. Journal of Hepatology, 65, 938-943.
https://doi.org/10.1016/j.jhep.2016.05.044
|
[39]
|
Wang, K., Guo, W.X., Chen, M.S., et al. (2016) Multimodality Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. Medicine, 95, e3015.
https://doi.org/10.1097/MD.0000000000003015
|
[40]
|
Liu, S., Guo, L., Li, H., et al. (2018) Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus. Annals of Surgical Oncology, 25, 2098-2104.
https://doi.org/10.1245/s10434-018-6438-1
|